Although mortality rates associated with cardiovascular disease have decreased significantly in high-income countries in recent decades, substantial challenges related to CVD treatment and outcomes persist in rural areas.
According to recent estimates from the Centers for Disease Control and Prevention, stroke affects more than 795,000 individuals in the United States annually and represents the fifth leading cause of death in the country.1 Stroke is also associated with substantial long-term disability and with costs estimated at $34 billion each year. Atrial fibrillation (AF), which…
Jemima Albayda, MD, discusses the cardiac complications in idiopathic inflammatory myopathies.
Although high-density lipoprotein cholesterol has been deemed the “good cholesterol,” this label may be misleading and outdated given that there is little evidence to support a causal relationship with CVD risk reduction.
The most recent CHEST guidelines on pulmonary arterial hypertension treatment support the integration of palliative care, noting significant improvements in outcomes observed in other pulmonary diseases, including lung cancer.
The optimal treatment approach for pulmonary arterial hypertension in pediatric patients depends upon the severity and underlying etiology of the disease.
In a review of repurposing medications for pulmonary arterial hypertension treatment, dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support their use.
It is estimated that more than 166 million Americans use dietary supplements and many healthcare providers are unfamiliar with how and whether these substances are regulated by the FDA.
Are dietary supplements necessary?
Individuals with gout have been shown to carry a significantly greater risk for cardiovascular (CV) events and CV-related mortality compared with those without gout.
